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Abstract
Background: Artemether/lumefantrine (AL) has been adopted as the treatment of choice for
uncomplicated malaria in Kenya and other countries in the region. Six-dose artemether/
lumefantrine tablets are highly effective and safe for the treatment of infants and children weighing
between five and 25 kg with uncomplicated Plasmodium falciparum malaria. However, oral paediatric
formulations are urgently needed, as the tablets are difficult to administer to young children, who
cannot swallow whole tablets or tolerate the bitter taste of the crushed tablets.
Methods: A randomized, controlled, open-label trial was conducted comparing day 28 PCR
corrected cure-rates in 245 children aged 6–59 months, treated over three days with either six-
dose of artemether/lumefantrine tablets (Coartem®) or three-dose of artemether/lumefantrine
suspension (Co-artesiane®) for uncomplicated falciparum malaria in western Kenya. The children
were followed-up with clinical, parasitological and haematological evaluations over 28 days.
Results: Ninety three percent (124/133) and 90% (121/134) children in the AL tablets and AL
suspension arms respectively completed followed up. A per protocol analysis revealed a PCR-
corrected parasitological cure rate of 96.0% at Day 28 in the AL tablets group and 93.4% in the AL
suspension group, p = 0.40. Both drugs effectively cleared gametocytes and were well tolerated,
with no difference in the overall incidence of adverse events.
Conclusion: The once daily three-dose of artemether-lumefantrine suspension (Co-artesiane®)
was not superior to six-dose artemether-lumefantrine tablets (Coartem®) for the treatment of
uncomplicated malaria in children below five years of age in western Kenya.
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Background
Resistance to the commonly used anti-malarial drugs has
probably contributed substantially to the increased mor-
bidity and mortality due to malaria [1]. As in many sub-
Saharan countries, resistance to chloroquine (CQ) and
subsequently resistance to sulphadoxine-pyrimethamine
(SP) constrained malaria control efforts in Kenya. In
2004, the Kenyan Ministry of Health promulgated a
change in the first-line treatment of uncomplicated
malaria, replacing SP with the fixed-dose combination of
artemether-lumefantrine tablets (Coartem®), which, at the
time, was the only co-formulated artemisinin-based com-
bination therapy (ACT) [2].
Previous studies in Africa have shown that the six-dose
regimen of artemether-lumefantrine (AL) tablets is safe,
efficacious and effective in the treatment of uncompli-
cated malaria in children less than five years of age, resid-
ing in areas with high levels of CQ and SP resistance [3-8].
Subsequently, several countries in sub-Saharan Africa
have adopted AL as the treatment of choice for uncompli-
cated malaria. However, the implementation of this treat-
ment policy change has faced several programmatic
challenges in Kenya and Zambia. There was at least a two-
year time lag between policy change and early implemen-
tation, partly due to lack of sustainable financing and
weak health systems. Initial studies have cited lower
degrees of preparedness by health facilities and workers
resulting in sub-optimal quality of treatment at the point
of care, due to irregular drug supply, inconsistent training
and lack of supervision [2,9-11].
Although children less than five years of age are the major
target of anti-malarial drug therapy in malaria endemic
regions, the available oral paediatric formulations of ACT
are not optimal for this high-risk population; young chil-
dren cannot swallow whole tablets and sometimes spit
out the drug, because of the bitter taste of the crushed tab-
lets. In addition, AL tablets are not recommended for
patients weighing less than 5 kg. These drug administra-
tion problems influence prescription of ACT by health
workers and patient adherence, resulting in either under-
dosing or over-dosing. Within the context of home-based
management of malaria, 10 – 20% of participants were
either non-adherent or administered incorrect doses of AL
tablets [12-14]. There is an urgent need for oral prepara-
tions of ACTs for young children, which are easy to
administer and stable under tropical conditions. Evalua-
tion of an AL paediatric dispersible tablet has been com-
pleted, showing good efficacy (Salim Abdulla, personal
communication). Artemether/lumefantrine powder for
suspension is a fixed-dose combination of the two anti-
malarials developed by Dafra Pharma NV in 2004 and
manufactured by Manufacturing Packaging Farmaca
(MPF) b.v. in the Netherlands under GMP. AL suspen-
sionwas shown to be safe and efficacious in pre-registra-
tion trials in paediatric patients in Zambia, Sudan and
Ivory Coast [15-17] (Additional file 1).
Materials and methods
Study site
This study was conducted at Chulaimbo Health Centre in
Kisumu District in western Kenya. The facility serves a pre-
dominantly rural population in an area with high peren-
nial malaria transmission in the lowlands around Lake
Victoria. Transmission peaks during the long rains
(March–May) and the short rains (October–December).
The annual entomological inoculation rate in the sur-
rounding area was 31.1 infectious bites/person/year for
12 months ending June 2004 [18]. More than 95% of
infections are caused by P. falciparum, with the remaining
being mixed P. falciparum with Plasmodium malariae and
rarely Plasmodium ovale infections. In vivo drug resistance
to SP in children <5 years is 74.5% [19,20] and 59% to
amodiaquine [21].
Patient screening and recruitment
A 2003 WHO protocol for the assessment and monitoring
of anti-malarial drug efficacy for the treatment of uncom-
plicated falciparum malaria was used [22]. Children pre-
senting to the health facility were screened for eligibility
and invited to participate in the study if they met the fol-
lowing inclusion criteria: aged 6–59 months; body weight
≥ 5 kg; a history of fever in the previous 24 hours or meas-
ured fever (axillary temperature ≥ 37.5°C); monoinfec-
tion with P. falciparum, with parasitaemia in the range of
2,000–200,000 asexual parasites per microlitre of blood;
no other cause for fever than suspected malaria; and, no
general danger signs or signs of severe and complicated
falciparum malaria as per WHO guidelines [23].
Study design, randomization and treatment
A randomized, controlled, open-label trial design was
used. PCR-corrected cure rate by day 28 after first dose was
the primary endpoint used for computing sample size.
Assuming a 94% cure rate with artemether-lumefantrine
tablets and 99.9% with the artemether-lumefantrine sus-
pension, a sample of 134 children was required (i.e. 127,
including 5% adjustment for loss to follow up) in each
treatment arm to detect this 6% difference in the parasito-
logical cure rates, with 80% power using a two-sided
alpha of 0.05. The randomization code was computer-
generated without stratification from which treatment
groups were assigned.
At enrolment, a medical history was obtained from par-
ents/guardians including presenting symptoms, current
medications, previous anti-malarial use and bed net use.
A physical examination was performed, weight and axil-
lary temperatures recorded and finger prick bloodMalaria Journal 2008, 7:262 http://www.malariajournal.com/content/7/1/262
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obtained for malaria smears, haemoglobin and blotted on
filter paper for parasite genotyping.
Consecutively eligible children were randomly assigned
into one of two treatment groups according to the rand-
omization code. A study nurse prepared and administered
the study medications, according to the treatment assign-
ment. One group received 6 doses of artemether/lumefan-
trine 20/120 mg tablets (Coartem®, Novartis AG),
crushed, mixed with water and administered at hours 0, 8,
24, 36, 48 and 60 over 3 days while the second group
received artemether/lumefantrine powder for suspension
(Co-artesiane® Dafra Pharma NV) containing 15 mg arte-
mether and 90 mg lumefantrine per 5 ml after reconstitu-
tion. A bottle of suspension was prepared for each child
and administered once daily at hour 0, 24 and 48 over 3
days. Treatment doses were calculated based on patient
weight and the administration directly observed under in-
patient care. All children were given a glass of milk or
breast fed (for those still breastfeeding) after drug admin-
istration since treatment times did not always coincide
with meals. They were then observed for 30 minutes after
drug administration for vomiting. If vomiting occurred,
the whole treatment dose was re-administered. If the re-
treatment dose was vomited, rescue treatment with
parenteral quinine was administered and the child was
withdrawn from the study.
All treatment failures were treated with oral or parenteral
quinine for 7 days depending on clinical presentation.
Paracetamol was administered to children with tempera-
ture ≥ 38.0°C or at the clinician's discretion. Antihelmin-
thics were given to all children >1 year who had not
received any in the past 3 months while children with hae-
moglobin <10 g/dl were treated with ferrous sulphate for
14 days. Long lasting insecticide treated bed nets (Olyset®,
Sumitomo Corp) were given to the children on comple-
tion of the study.
Follow-up
All children in the study were admitted to hospital for 3
days for observed drug administration and followed up
for a total of 28 days. Clinical and parasitological evalua-
tion was performed during hospitalization (days 0, 1, 2
and 3) and at the study clinic during scheduled visits on
days 7, 14, and 28, after initiating study treatment, or on
any other day if the child was unwell. During each sched-
uled visit, a brief clinical history was obtained and a phys-
ical examination was performed; blood smears for
malaria parasites and filter paper spot samples were
obtained. Patients who did not return to the clinic for
scheduled visits by mid day were visited at home by the
social worker and asked to come to the health facility.
Patients were excluded from the study if they; 1) withdrew
consent, 2) left the study area, or 3) reported taking anti-
malarial medication during follow-up.
Laboratory evaluation
Blood was drawn from a finger prick to prepare thick and
thin blood smears on days 0, 1, 2, 3, 7, 14, 28 and on any
other unscheduled visit. The smears were air dried, stained
with 3% Giemsa for 30 – 45 minutes and read independ-
ently by two technologists. Parasite density was calculated
by counting asexual parasites against a 500 leucocytes
assuming a leukocyte count of 8,000/μL of blood to
obtain number of parasites and gametocytes per microli-
tre (μL). Thin smears were examined for plasmodium par-
asite speciation. A slide was considered negative after
scanning 100 high power fields. A third microscopist
independently read discrepant slides. Haemoglobin was
measured using HemoCue® (HemoCue AB Angelholm,
Sweden) on Days 0, 7, 14 and 28. Filter paper blood spots
were collected on Days 0, 14 and 28 or any other day of
recurrent parasitaemia. Paired filter paper samples of chil-
dren who had parasitaemia during follow-up were used to
extract parasite DNA for PCR to distinguish recrudescent
from new infections as described by Snounou et al. [24].
Block 2 of MSP-1 and block 3 of MSP-2 were amplified by
nested PCR and size polymorphisms identified by gel
electrophoresis against a 100-basepair (bp) molecular
weight marker (New England Biolabs, Beverly, MA). Para-
sites were classified as recrudescent if they shared any of
the bands that were present on day 0 and as new infec-
tions if there were no common bands.
Ethical approval
This study was approved by the Kenya National/Kenya
Medical Research Institute Ethics Committee. Written
informed consent was obtained from all parents or guard-
ians of eligible children prior to enrolment.
Statistical analysis
Data from case report forms were checked, double entered
and verified for errors using Epi Info 2002 (Centers for
Disease Control and Prevention, Atlanta, GA USA). Data
was analysed using SPSS (v.12, SPSS Inc. Chicago, IL USA)
and Epi-Info 2002. The primary efficacy endpoint was day
28 PCR-corrected parasitological cure rate, defined as the
proportion of patients without asexual parasitaemia
within 7 days after beginning treatment, without recrudes-
cence within 28 days after beginning treatment and who
demonstrated no need for rescue treatment for signs of
clinical malaria within 28 days after initiation of study
treatment. Secondary end-points included PCR-corrected
parasitological cure rate on day 14, gametocyte carriage,
fever and parasite clearance rate. The intent to treat (ITT)
population defined as all randomized patients who took
at least one dose of study medication was used for safety
analysis. Proportions were compared between treatmentMalaria Journal 2008, 7:262 http://www.malariajournal.com/content/7/1/262
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groups using the chi-square test. Normally distributed var-
iables were compared using the Student's t-test and analy-
sis of variance (ANOVA). For skewed data, medians were
computed and comparisons made using the Kruskal-Wal-
lis one way ANOVA. Two tailed p-values < 0.05 were con-
sidered statistically significant.
Results
Participant characteristics
Two hundred and sixty seven of the 1327 children
screened for malaria were enrolled into the trial; 134 in
the AL suspension arm and 133 in the AL tablets arm. Sev-
enteen (6.4%) children withdrew or were lost to follow
up. Three (1.1%) children, all from the AL suspension
arm, were excluded from analysis due to age >59 months,
low weight for age and treatment with amodiaquine
within three days of enrolment. Two children in the AL
suspension arm were withdrawn from treatment due to
repeated vomiting on Day 0. Data from 245 children was
analysed; 124 in the AL tablets arm and 121 in the AL sus-
pension arm (Figure 1). Both treatment groups were com-
parable in terms of baseline demographic, clinical and
laboratory characteristics (Table 1).
Parasitological cure rates
There were two (0.7%) early treatment failures. One child
in the AL tablets arm developed severe anaemia (Hb < 5.0
g/dl) on Day 1 and was withdrawn from treatment while
another child in the AL suspension arm developed con-
vulsions on Day 0 and received treatment for severe
malaria. Both children recovered after treatment. The PCR
corrected cure rate for day 14 was 100% in the AL tablets
arm and 98.4% in the AL suspension arm while the day 28
cure rates were 96% (95% 95% CI 90.8 – 98.7) in the AL
tablets arm and 93% (95% CI 87.4 – 97.1) in the AL sus-
pension arm p = 0.40 (Table 2). The re-infection rate was
9.6% in the AL tablets arm and 5.7% in the AL suspension
arm (p = 0.25).
Fever, parasite and gametocyte clearance
The proportions of children with fever (temperature ≥
37.5°C), and parasitaemia over the first four days, and
anaemia (haemoglobin < 10 g/dl) over the 28 day follow-
up period were similar in both treatment groups (Figures
2, 3, 4). Fourteen (11.2%) and 10 (8.2%) of children in
the AL tablets and AL suspension arms, respectively, had
gametocytes on Day 0. Both treatments were effective in
clearing gametocytes with only one participant in each
treatment arm having gametocytes on Day 7 and none by
Day 28.
Adverse events
There was no difference in the incidence of vomiting
between the treatment groups as a proportion of treat-
ment doses administered over the first 3 days of treat-
ment: AL tablets arm, 21/807 (2.6%) and AL suspension
arm, 12/406 (3.0%), p = 0.72. Two patients (one in each
arm) had diarrhoea, which was suspected to be due to the
drugs.
Seven Serious Adverse Events (SAE) were recorded during
the trial, four in the AL tablets arm and three in the AL sus-
Table 1: Baseline characteristics of children enrolled in the trial
Characteristic AL tablets
N = 124
AL suspension
N = 121
p
Female sex (%) 65 (52.4) 58 (47.9) 0.52
Prior anti-malarial use (2 months) N (%) 3 (2.4) 1 (0.8) 0.62
ITN use N (%) 55 (44.4) 58 (47.9) 0.49
Median age in months (+ SD) 28 (16.3) 25 (15.6) 0.63
Mean weight in kg (+ SD) 11.4 (3.3) 11.7 (3.1) 0.38
Mean temperature °C (+ SD) 38.1 (1.2) 38.2 (1.2) 0.70
Mean* parasitaemia per μl (range) 25,231 (2008 – 195288) 34,881 (2111 – 196343) 0.37
Mean haemoglobin g/dl (+ SD) 9.5 (2.1) 9.7 (1.9) 0.38
Proportion with gametocytes N (%) 14 (11.2) 10 (8.2) 0.42
Mean dose A/L mg (SD) 124 (49)/871 (294) 121 (40)/807 (239) 0.06Malaria Journal 2008, 7:262 http://www.malariajournal.com/content/7/1/262
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The trial profile Figure 1
The trial profile.
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pension arm, none of which was considered related to the
study drugs. Three (2.4%) children in the AL tablets arm
developed severe anaemia (haemoglobin<5.0 g/dl) dur-
ing the study. One child developed severe anaemia on
Day 1 and was withdrawn from the intervention, while
the other two had severe anaemia detected on Day 7 dur-
ing a routine follow-up visit. All three children with severe
anaemia were enrolled with haemoglobin between 5–7 g/
dl and were treated with iron supplementation only. The
fourth child (0.8%) developed severe malaria on day 26
during follow-up. In the AL suspension arm, one child
developed severe malaria and meningitis on Day 0 and
was withdrawn from treatment, he subsequently devel-
oped neurological sequelae. The other children each
developed severe malaria (day 22) and severe pneumonia
(day 28) and recovered completely. Other adverse events
are summarized in Table 3.
Table 2: PCR corrected clinical and parasitological responses on Days 14 and 28
AL tablets AL suspension p
Day 14 cure rate, no. (%) 127/127 (100) 122/124 (98.4) 0.24
Day 28 cure rate, no. (%) 119/124 (96.0)
95% CI 90.8 – 98.7
113/121 (93.4)
95% CI 87.4 – 97.1
0.40
Proportion of children with fever during treatment Figure 2
Proportion of children with fever during treatment.Malaria Journal 2008, 7:262 http://www.malariajournal.com/content/7/1/262
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Discussion
The 28 day PCR corrected efficacy of AL suspension was
93.4% compared with 96.0% for AL tablets (p = 0.40).
Previous trials reported efficacy rates between 98 – 100%
for AL suspension in various parts of Africa [15-17]. The
efficacy of the AL tablets in this study was consistent with
95.4% efficacy obtained in the same region in 2004 prior
to introduction of AL as first line treatment for uncompli-
cated malaria in Kenya (Juma et al, unpublished data).
The process of changing national treatment policies for
malaria is complex and the costs involved are substantial
[2,25,26]. Conceivably, it may be equally difficult for
both health workers and caretakers of sick children to
implement a change in drug formulations. Proper con-
duct of such policy changes should be evidence-based.
This study provides some evidence for policy and clinical
practice in use of AL as the first line treatment in Kenya
and like countries in the region. For the first time, an
investigation was carried out to compare the efficacy and
safety of the AL suspension with the AL tablets, and no
evidence was found that the suspension is less efficacious.
Both AL preparations have a fixed-dose artemether to
lumefantrine ratio of 1:6 with doses calculated to give an
average of 4 mg/kg artemether per day. The AL tablet
requires twice daily doses while the AL suspension has the
advantage of single daily administration. A previous study
also found that the AL suspension is safe to administer to
children below 5 kg of weight [15]. One disadvantage of
the suspension is the narrow weight range (2.0 kg for
given dose – which calls for proper reconstitution and
good dispensing practice) compared with 10 kg for a
given dose of AL tablets.
The major motivation to evaluate this suspension was the
limitations of administering hard tablets to children espe-
cially the very young, by mothers and health workers.
These difficulties notwithstanding, AL tablets are effica-
cious and effective in this age-group. Although not widely
available, an AL dispersible tablet for paediatric patients is
currently under review by regulatory authorities. AL sus-
pension and probably the AL paediatric dispersible tablet
will be useful alternatives and a milestone in the treat-
ment of uncomplicated malaria in young children who
Proportion of children with haemoglobin <10 g/dL Figure 3
Proportion of children with haemoglobin <10 g/dL.
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are unable to take AL tablets. Further studies are needed to
evaluate the effect of widening the weight-based dosing
ranges of AL suspension for ease of dispensing and admin-
istration. This study did not focus on the safety by body
weight and future studies should investigate this aspect
(see additional file 2).
PCR-corrected cure rates were used as the primary efficacy
endpoint. Coupled with a comparative randomized
design, the results obtained in the trial reflect a valid
measure of the AL suspension's efficacy and also provides
evidence of non-declining efficacy of AL in the treatment
of uncomplicated malaria in children in western Kenya
known to be the hot bed of anti-malarial drug resistance
in Africa. There were two recrudescent parasitological
treatment failures in children on the AL suspension arm at
Day 14. These children did not vomit or spit out the study
medication, had levels of parasitaemia of 4376/μl and
42,640/μl respectively and were free of parasites by day-2
of treatment. All previous studies have reported 100%
ACPR at day-14 with the AL suspension. The reasons for
this are unclear and may need to be investigated further,
especially day-7 lumefantrine blood levels. AL suspension
is given once daily and lumefantrine absorption can be
erratic in some children [27]. As expected both treatment
regimens were effective in shortening the fever, parasite
clearance times and reduction of gametocyte carriage.
Both regimens were well tolerated with the incidence of
vomiting in the first three days of treatment being similar
for both groups. Other adverse events reported during fol-
low-up occurred similarly between treatment groups and
included respiratory infections (21.7%), malaria (11.2%)
and skin infections (8.6%), none attributed to the study
medications.
Proportion of children with parasites during the first three days after treatment Figure 4
Proportion of children with parasites during the first three days after treatment.
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This trial had several limitations. The open label design
could bias the results because the parents of the children
were aware of their children's treatment assignment. Chil-
dren were not followed up to 42 days as recommended by
WHO guidelines [22]. However, the population in the
catchment area of our study site is exposed to high peren-
nial transmission of malaria and a longer follow-up
period would most likely show more cases with re-infec-
tion than recrudescence to impact final efficacy outcomes.
The power of this study computed post hoc was only 65%,
indicating that the sample size studied was not sufficient
to detect a significant difference in efficacy between the
two treatment formulations. Furthermore, this study was
conducted under supervised conditions and may not
reflect the realities of treatment practices in normal outpa-
tient care. Larger trials to confirm non-inferiority between
these two formulations are recommended.
Conclusion
The once daily 3-dose of artemether-lumefantrine suspen-
sion (Co-artesiane®) was not superior to 6-dose arte-
mether-lumefantrine tablets (Coartem®) for the treatment
of uncomplicated malaria in children below 5 years of age
in western Kenya.
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Table 3: Summary of Adverse Events
Adverse event AL tablets
n = 133* (%)
AL suspension
n = 134* (%)
p
Diarrhoea 11 (8.3) 10 (7.4) 0.81
Vomiting during treatment** 21 (2.6) 12 (3.0) 0.72
Rhinitis 17(12.8) 22 (16.4) 0.40
Otitis Media 1 (0.8) 5 (3.7) 0.21
Pneumonia 3 (2.3) 6 (4.5) 0.50
Bacterial skin infections 5 (3.8) 5 (3.7) 1.00
Fungal skin infections 6 (4.5) 5 (3.7) 0.98
Eczematous rash 1(0.8) 5 (3.7) 0.21
Contact dermatitis 1 (0.8) 1 (0.7) 1.00
Conjunctivitis 6 (4.5) 7 (5.2) 0.98
* n = total number of children randomized to the treatments
** Vomiting episodes as a proportion of number of treatment doses 
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